Skip to main content
ACB
NASDAQ Life Sciences

Aurora Cannabis Urges Shareholders to Take No Action on Curaleaf's Hostile Bid

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$3.65
Mkt Cap
$238.043M
52W Low
$2.56
52W High
$6.665
52W Position info
43% above low
Off High info
45% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ACB sits 43% above its 52-week low of $2.56.

Summary

Curaleaf formally launched its hostile takeover bid for Aurora Cannabis at US$4.00 per share. Aurora's board formed a special committee and urged shareholders to take no action until a recommendation is issued within 15 days.


Key Events · M&A and Partnerships · ACB

  • Formal Takeover Bid Commenced

    Curaleaf formally commenced its unsolicited takeover bid for all Aurora shares at US$4.00 per share, consisting of 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, capped at US$5.00 per share.

  • Board Forms Special Committee

    Aurora's board formed a special committee of independent directors to evaluate the offer and will provide a formal recommendation within 15 days via a Directors' Circular.

  • Shareholders Advised to Take No Action

    Aurora urged shareholders to take no action on the offer until the board's formal recommendation is issued.

  • Offer Open for 105 Days

    The offer will remain open for a minimum of 105 days, allowing shareholders until at least December 1, 2026 to consider their options.


Analysis · ACB · Life Sciences

Curaleaf has formally commenced its unsolicited takeover bid for Aurora Cannabis at US$4.00 per share, consisting of 0.3463 Curaleaf shares plus US$0.75 in cash, capped at US$5.00. Aurora's board has formed a special committee and advises shareholders to take no action until a formal recommendation is issued within 15 days. The bid remains open for at least 105 days, until December 1, 2026. This formal commencement adds procedural clarity to the hostile bid first announced on August 11, 2026, and sets the clock for Aurora's response.

At the time of this filing, ACB was trading at $3.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACB - Latest Insights

ACB
Aug 13, 2026, 11:38 AM EDT
Filing Type: 6-K
Importance Score:
8
ACB
Aug 11, 2026, 3:43 PM EDT
Filing Type: 6-K
Importance Score:
9
ACB
Aug 11, 2026, 8:25 AM EDT
Source: PR Newswire
Importance Score:
9
ACB
Aug 05, 2026, 7:46 AM EDT
Filing Type: 6-K
Importance Score:
8
ACB
Aug 05, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
8